Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG (ECU-MG-304)

Alexion Pharmaceuticals

Status and phase

Completed

Phase 3

Conditions

Generalized Myasthenia Gravis (gMG)

Refractory gMG

Treatments

Drug: Eculizumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT06764160

D7411C00003

ECU-MG-304 (Other Identifier)

Details and patient eligibility

About

This is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG. Approximately 15 participants will be enrolled in the study.

Full description

This post-approval study is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG. There will be 3 periods in this study: Screening Period (up to 4 weeks), Treatment Period (26 weeks, including an Induction Phase and a Maintenance Phase), and Safety Follow-up Period (8 weeks). The overall study duration for an individual participant is estimated to be up to 38 weeks. Approximately 15 participants will be enrolled in the study.

Enrollment

15 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of MG must be made by the following tests:
1. Positive serologic test for anti-AChR Abs as confirmed at Screening, and
2. One of the following:
  1. Abnormal neuromuscular transmission demonstrated by repetitive nerve stimulation, or
  2. History of positive anticholinesterase test, eg, neostigmine test, or
  3. Participant has demonstrated improvement in MG signs on oral cholinesterase inhibitors as assessed by the treating physician
MGFA Clinical Classification Class II to IV at Screening
MG-ADL total score must be ≥ 6 at Screening and Day 1
Participants who have:
1. Failed treatment with 2 or more ISTs over one year (either in combination or as monotherapy), ie, continue to have impairment ADLs (persistent weakness, experience crisis, or unable to tolerate IST) despite ISTs or,
2. Failed at least one IST and require chronic PE or IVIg to control symptoms, ie, participants who require PE or IVIg on a regular basis for the management of muscle weakness at least 2 cycles over last 12 months

Exclusion criteria

Any untreated thymic malignancy, carcinoma, or thymoma
History of thymectomy or any other thymic surgery within 6 months prior to Screening. Participants with a history of treated thymic malignancy or carcinoma are eligible if they meet all of the following conditions:
1. Treatment completed > 5 years prior to the Screening Visit
2. No recurrence within the 5 years prior to the Screening Visit
3. No radiological indication of recurrence in a computed tomography (CT) or magnetic resonance imaging (MRI) scan, including administration of intravenous (IV) contrast, performed within 6 months of first dose on Day 1
Weakness only affecting ocular or peri-ocular muscles (MGFA Class I)
MG crisis at Screening (MGFA Class V). However, such participants may be rescreened with Alexion approval once they are treated and medically stable, in the opinion of the Investigator
History of N meningitidis infection or unresolved meningococcal disease